Incyte Corporation (INCY) - Total Assets
Based on the latest financial reports, Incyte Corporation (INCY) holds total assets worth $7.34 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check INCY total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Incyte Corporation - Total Assets Trend (1993–2025)
This chart illustrates how Incyte Corporation's total assets have evolved over time, based on quarterly financial data. Explore Incyte Corporation strategic investment ratio to see how much of total assets are deployed in long-term investments.
Incyte Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Incyte Corporation's total assets of $7.34 Billion consist of 72.2% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.5% |
| Accounts Receivable | $1.02 Billion | 14.7% |
| Inventory | $101.06 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $117.13 Million | 1.7% |
| Goodwill | $133.00 Million | 1.9% |
Asset Composition Trend (1993–2025)
This chart illustrates how Incyte Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Incyte Corporation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Incyte Corporation's current assets represent 72.2% of total assets in 2025, a decrease from 89.2% in 1993.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2025, down from 88.1% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 14.7% of total assets.
Incyte Corporation Competitors by Total Assets
Key competitors of Incyte Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Incyte Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.68 | 2.04 | 3.97 |
| Quick Ratio | 3.60 | 2.00 | 3.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.99 Billion | $1.79 Billion | $1.96 Billion |
Incyte Corporation - Advanced Valuation Insights
This section examines the relationship between Incyte Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.50 |
| Latest Market Cap to Assets Ratio | 2.84 |
| Asset Growth Rate (YoY) | 27.8% |
| Total Assets | $6.96 Billion |
| Market Capitalization | $19.78 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Incyte Corporation's assets at a significant premium (2.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Incyte Corporation's assets grew by 27.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Incyte Corporation (1993–2025)
The table below shows the annual total assets of Incyte Corporation from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.96 Billion | +27.80% |
| 2024-12-31 | $5.44 Billion | -19.73% |
| 2023-12-31 | $6.78 Billion | +16.11% |
| 2022-12-31 | $5.84 Billion | +18.40% |
| 2021-12-31 | $4.93 Billion | +38.54% |
| 2020-12-31 | $3.56 Billion | +3.92% |
| 2019-12-31 | $3.43 Billion | +29.52% |
| 2018-12-31 | $2.65 Billion | +14.90% |
| 2017-12-31 | $2.30 Billion | +40.52% |
| 2016-12-31 | $1.64 Billion | +62.65% |
| 2015-12-31 | $1.01 Billion | +21.37% |
| 2014-12-31 | $830.07 Million | +31.85% |
| 2013-12-31 | $629.57 Million | +90.54% |
| 2012-12-31 | $330.42 Million | +0.44% |
| 2011-12-31 | $328.96 Million | -32.81% |
| 2010-12-31 | $489.58 Million | -31.28% |
| 2009-12-31 | $712.39 Million | +206.55% |
| 2008-12-31 | $232.39 Million | -15.71% |
| 2007-12-31 | $275.69 Million | -22.03% |
| 2006-12-31 | $353.60 Million | -5.48% |
| 2005-12-31 | $374.11 Million | -27.63% |
| 2004-12-31 | $516.92 Million | +36.19% |
| 2003-12-31 | $379.55 Million | -31.26% |
| 2002-12-31 | $552.14 Million | -21.74% |
| 2001-12-31 | $705.56 Million | -20.44% |
| 2000-12-31 | $886.82 Million | +299.65% |
| 1999-12-31 | $221.90 Million | -3.65% |
| 1998-12-31 | $230.30 Million | +19.26% |
| 1997-12-31 | $193.10 Million | +188.64% |
| 1996-12-31 | $66.90 Million | +15.74% |
| 1995-12-31 | $57.80 Million | +101.39% |
| 1994-12-31 | $28.70 Million | +63.07% |
| 1993-12-31 | $17.60 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more